Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 8/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | ALKBH1 | Q13686 | 2/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17668740 | 0.87 | KMT2A (0.46) | KMT2ALMNABACE1BACE2MEN1 | |
| SCHEMBL17173723 | 0.86 | KMT2A (0.45) | KMT2ALMNABACE1BACE2MEN1 | |
| SCHEMBL10323018 | 0.86 | KMT2A (0.45) | KMT2ALMNABACE1BACE2MEN1 | |
| SCHEMBL2716239 | 0.84 | PRKAB2 (0.47) | KMT2AMEN1RAB9ATDP1FFAR4 | |
| SCHEMBL18662107 | 0.83 | KMT2A (0.46) | KMT2ALMNABACE1BACE2MEN1 | |
| SCHEMBL10328693 | 0.82 | KMT2A (0.38) | KMT2ALMNABACE1BACE2MEN1 | |
| SCHEMBL14721176 | 0.81 | BACE1 (0.41) | KMT2ALMNABACE1BACE2MEN1 | |
| SCHEMBL363130 | 0.81 | BACE1 (0.42) | BACE1BACE2APPCYP2D6 | |
| SCHEMBL17160932 | 0.80 | ALDH1A1 (0.47) | KMT2ALMNABACE1BACE2MEN1 | |
| SCHEMBL360439 | 0.79 | TDP1 (0.39) | KMT2ALMNABACE1BACE2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2663561-B1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2016-03-16 | — | — | EP | claimed |
| US-20150203481-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2015-07-23 | — | — | US | claimed |
| EP-2663559-B1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-07-01 | — | — | EP | claimed |
| EP-2456763-B1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-01-21 | — | — | EP | claimed |
| US-20150018338-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-01-15 | — | — | US | claimed |
| US-8865712-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | claimed |
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2014-05-08 | — | — | US | claimed |
| US-20140107118-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2014-04-17 | — | — | US | claimed |
| US-8637508-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2014-01-28 | — | — | US | claimed |
| EP-2663559-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2013-11-20 | — | — | EP | claimed |
| EP-2663308-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2013-11-20 | — | — | EP | claimed |
| EP-2663561-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2013-11-20 | — | — | EP | claimed |
| US-20130281449-A1 | Oxazine Derivatives and their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | claimed |
| EP-2483255-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2012-08-08 | — | — | EP | claimed |
| US-20120184539-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-07-19 | — | — | US | claimed |
| WO-2012095463-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | claimed |
| WO-2012095521-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | claimed |
| WO-2012095469-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | claimed |
| WO-2012006953-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-01-19 | — | — | WO | claimed |
| CN-107683283-B | BACE1 inhibitors | 豪夫迈·罗氏有限公司 | 2021-05-18 | — | — | CN | disclosed |
| US-10696691-B2 | BACE1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10683287-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2020-06-16 | — | — | US | disclosed |
| US-20200048236-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2020-02-13 | — | — | US | disclosed |
| US-20190270757-A1 | BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-09-05 | — | — | US | disclosed |
| CN-106458956-B | The heterocycle sulfone that heteroaryl replaces | 格吕伦塔尔有限公司 | 2019-06-14 | — | — | CN | disclosed |
| US-10301296-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2019-05-28 | — | — | US | disclosed |
| EP-3334742-B1 | BACE1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-05-08 | — | — | EP | disclosed |
| CN-106795177-B | BACE1 inhibitors | 豪夫迈·罗氏有限公司 | 2019-04-23 | — | — | CN | disclosed |
| US-10253042-B2 | N-(2-(2-amino-6-substituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]oxazin-8a(8H)-YL)-thiazol-4-YL) amides | PFIZER INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-10253042-B2 | N-(2-(2-amino-6-substituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]oxazin-8a(8H)-YL)-thiazol-4-YL) amides | PFIZER INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-10246468-B2 | BACE1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20190002476-A1 | BACE1 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2019-01-03 | — | — | US | disclosed |
| US-10112958-B2 | N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-YL)-1,3-thiazol-4-YL] amides | PFIZER INC. (US) | 2018-10-30 | — | — | US | disclosed |
| EP-3204391-B1 | BACE1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2018-08-29 | — | — | EP | disclosed |
| EP-3353182-A1 | TETRAHYDROPYRANO[3,4-D][1,3]OXAZIN DERIVATIVES AND THEIR USE AS BACE INHIBITORS | Pfizer Inc (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-3353183-A1 | N-[2-(2-AMINO-6,6-DISUBSTITUTED-4, 4A, 5, 6-TETRAHYDROPYRANO [3,4-D][1,3]THIAZIN-8A (8H)-YL) -1, 3-THIAZOL-4-YL]AMIDES | Pfizer Inc (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-3353174-A1 | N-[2-(3-AMINO-2,5-DIMETHYL-1,1-DIOXIDO-5,6-DIHYDRO-2H-1,2,4-THIADIAZIN-5-YL)-1,3-THIAZOL-4-YL]AMIDES USEFUL AS BACE INHIBITORS | Pfizer Inc (US) | 2018-08-01 | — | — | EP | disclosed |
| US-10035794-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2018-07-31 | — | — | US | disclosed |
| EP-3334742-A1 | BACE1 INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2018-06-20 | — | — | EP | disclosed |
| CN-107683283-A | Bace1 inhibitor | 豪夫迈·罗氏有限公司 | 2018-02-09 | — | — | CN | disclosed |
| US-20170369506-A1 | N-(2-(2-AMINO-6-SUBSTITUTED-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]OXAZIN-8a(8H)-YL)-THIAZOL-4-YL) AMIDES | PFIZER INC. (US) | 2017-12-28 | — | — | US | disclosed |
| US-20170369506-A1 | N-(2-(2-AMINO-6-SUBSTITUTED-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]OXAZIN-8a(8H)-YL)-THIAZOL-4-YL) AMIDES | PFIZER INC. (US) | 2017-12-28 | — | — | US | disclosed |
| US-20170320864-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2017-11-09 | — | — | US | disclosed |
| US-20170305931-A1 | N-[2-(2-AMINO-6,6-DISUBSTITUTED-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL)-1,3-THIAZOL-4-YL] AMIDES | PFIZER INC. (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305931-A1 | N-[2-(2-AMINO-6,6-DISUBSTITUTED-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL)-1,3-THIAZOL-4-YL] AMIDES | PFIZER INC. (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305931-A1 | N-[2-(2-AMINO-6,6-DISUBSTITUTED-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL)-1,3-THIAZOL-4-YL] AMIDES | PFIZER INC. (US) | 2017-10-26 | — | — | US | disclosed |
| US-9771379-B2 | N-(2-(2-amino-6-substituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]OXAZIN-8a(8H)-yl)-thiazol-4-yl) amides | PFIZER INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771379-B2 | N-(2-(2-amino-6-substituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]OXAZIN-8a(8H)-yl)-thiazol-4-yl) amides | PFIZER INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771379-B2 | N-(2-(2-amino-6-substituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]OXAZIN-8a(8H)-yl)-thiazol-4-yl) amides | PFIZER INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9751895-B2 | N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl)-1,3-thiazol-4-yl]amides | PFIZER INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751895-B2 | N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl)-1,3-thiazol-4-yl]amides | PFIZER INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751895-B2 | N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl)-1,3-thiazol-4-yl]amides | PFIZER INC. (US) | 2017-09-05 | — | — | US | disclosed |
| EP-3204391-A1 | BACE1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2017-08-16 | — | — | EP | disclosed |
| CN-106795177-A | BACE1 inhibitors | 豪夫迈·罗氏有限公司 | 2017-05-31 | — | — | CN | disclosed |
| US-9611264-B1 | N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides | PFIZER INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9611264-B1 | N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides | PFIZER INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9611264-B1 | N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides | PFIZER INC. (US) | 2017-04-04 | — | — | US | disclosed |
| WO-2017051276-A1 | N-[2-(2-AMINO-6,6-DISUBSTITUTED-4, 4A, 5, 6-TETRAHYDROPYRANO [3,4-D][1,3] THIAZIN-8A (8H)-YL) -1, 3-THIAZOL-4-YL] AMIDES | PFIZER INC. (US) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017051276-A1 | N-[2-(2-AMINO-6,6-DISUBSTITUTED-4, 4A, 5, 6-TETRAHYDROPYRANO [3,4-D][1,3] THIAZIN-8A (8H)-YL) -1, 3-THIAZOL-4-YL] AMIDES | PFIZER INC. (US) | 2017-03-30 | — | — | WO | disclosed |
| US-20170088558-A1 | N-[2-(2-Amino-6,6-Disubstituted-4,4a,5,6-Tetrahydropyrano[3,4-d][1,3]Thiazin-8a(8H)-YL)-1,3-Thiazol-4-YL]Amides | PFIZER INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170088556-A1 | N-(2-(2-AMINO-6-SUBSTITUTED-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]OXAZIN-8a(8H)-YL)-THIAZOL-4-YL) AMIDES | PFIZER INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170088556-A1 | N-(2-(2-AMINO-6-SUBSTITUTED-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]OXAZIN-8a(8H)-YL)-THIAZOL-4-YL) AMIDES | PFIZER INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170088556-A1 | N-(2-(2-AMINO-6-SUBSTITUTED-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]OXAZIN-8a(8H)-YL)-THIAZOL-4-YL) AMIDES | PFIZER INC. (US) | 2017-03-30 | — | — | US | disclosed |
| WO-2017051303-A1 | TETRAHYDROPYRANO[3,4-D][1,3]OXAZIN DERIVATIVES AND THEIR USE AS BACE INHIBITORS | PFIZER INC. (US) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017051303-A1 | TETRAHYDROPYRANO[3,4-D][1,3]OXAZIN DERIVATIVES AND THEIR USE AS BACE INHIBITORS | PFIZER INC. (US) | 2017-03-30 | — | — | WO | disclosed |
| US-20170088547-A1 | N-[2-(3-AMINO-2,5-DIMETHYL-1,1-DIOXIDO-5,6-DIHYDRO-2H-1,2,4-THIADIAZIN-5-YL)-1,3-THIAZOL-4-YL] AMIDES | PFIZER INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170088547-A1 | N-[2-(3-AMINO-2,5-DIMETHYL-1,1-DIOXIDO-5,6-DIHYDRO-2H-1,2,4-THIADIAZIN-5-YL)-1,3-THIAZOL-4-YL] AMIDES | PFIZER INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170088547-A1 | N-[2-(3-AMINO-2,5-DIMETHYL-1,1-DIOXIDO-5,6-DIHYDRO-2H-1,2,4-THIADIAZIN-5-YL)-1,3-THIAZOL-4-YL] AMIDES | PFIZER INC. (US) | 2017-03-30 | — | — | US | disclosed |
| WO-2017051294-A1 | N-[2-(3-AMINO-2,5-DIMETHYL-1,1-DIOXIDO-5,6-DIHYDRO-2H-1,2,4-THIADIAZIN-5-YL)-1,3-THIAZOL-4-YL] AMIDES USEFUL AS BACE INHIBITORS | PFIZER INC. (US) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017051294-A1 | N-[2-(3-AMINO-2,5-DIMETHYL-1,1-DIOXIDO-5,6-DIHYDRO-2H-1,2,4-THIADIAZIN-5-YL)-1,3-THIAZOL-4-YL] AMIDES USEFUL AS BACE INHIBITORS | PFIZER INC. (US) | 2017-03-30 | — | — | WO | disclosed |
| US-20170088558-A1 | N-[2-(2-Amino-6,6-Disubstituted-4,4a,5,6-Tetrahydropyrano[3,4-d][1,3]Thiazin-8a(8H)-YL)-1,3-Thiazol-4-YL]Amides | PFIZER INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170088558-A1 | N-[2-(2-Amino-6,6-Disubstituted-4,4a,5,6-Tetrahydropyrano[3,4-d][1,3]Thiazin-8a(8H)-YL)-1,3-Thiazol-4-YL]Amides | PFIZER INC. (US) | 2017-03-30 | — | — | US | disclosed |
| WO-2017025491-A1 | BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-02-16 | — | — | WO | disclosed |
| US-9550758-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2017-01-24 | — | — | US | disclosed |
| US-9540397-B2 | BACE1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2017-01-10 | — | — | US | disclosed |
| WO-2016055496-A1 | BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-04-14 | — | — | WO | disclosed |
| US-20160102105-A1 | BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-04-14 | — | — | US | disclosed |
| EP-2663561-B1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2016-03-16 | — | — | EP | disclosed |
| US-20150203481-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2015-07-23 | — | — | US | disclosed |
| EP-2663559-B1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-07-01 | — | — | EP | disclosed |
| EP-2456763-B1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-01-21 | — | — | EP | disclosed |
| US-20150018338-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-01-15 | — | — | US | disclosed |
| US-8865712-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-8846658-B2 | Oxazine derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2014-09-30 | — | — | US | disclosed |
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2014-05-08 | — | — | US | disclosed |
| US-20140113894-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CN) | 2014-04-24 | — | — | US | disclosed |
| US-20140107118-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2014-04-17 | — | — | US | disclosed |
| US-20140088084-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | HOLZER PHILIPP (CH) | 2014-03-27 | — | — | US | disclosed |
| US-8637508-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2014-01-28 | — | — | US | disclosed |
| EP-2663561-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2013-11-20 | — | — | EP | disclosed |
| EP-2663308-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2013-11-20 | — | — | EP | disclosed |
| EP-2663559-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2013-11-20 | — | — | EP | disclosed |
| US-20130281449-A1 | Oxazine Derivatives and their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | disclosed |
| US-8338413-B1 | Oxazine derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2012-12-25 | — | — | US | disclosed |
| US-20120302558-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-11-29 | — | — | US | disclosed |
| US-20120238560-A1 | Oxazine Derivatives and their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2012-09-20 | — | — | US | disclosed |
| EP-2483255-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2012-08-08 | — | — | EP | disclosed |
| US-20120184539-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-07-19 | — | — | US | disclosed |
| WO-2012095463-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012095521-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012095469-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | disclosed |
| US-20120172359-A1 | Oxazine Derivatives and their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2012-07-05 | — | — | US | disclosed |
| US-8207164-B2 | Oxazine derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2012-06-26 | — | — | US | disclosed |
| EP-2456763-A1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2012-05-30 | — | — | EP | disclosed |
| WO-2012006953-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20110021520-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG | 2011-01-27 | — | — | US | disclosed |
| US-20110021520-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (29 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305931-A1 | N-[2-(2-AMINO-6,6-DISUBSTITUTED-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL)-1,3-THIAZOL-4-YL] AMIDES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, UGT1A8, TBXA2R | KMT2A 3138/4885LMNA 2429/4885BACE1 1372/4885 |
| US-20130281449-A1 | Oxazine Derivatives and their Use in the Treatment of Neurological Disorders | GRIK5, OTC, GRIN2C | KMT2A 1721/4885LMNA 2710/4885BACE1 74/4885 |
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | BACE2, BACE1, IAPP | KMT2A 2117/4885LMNA 3125/4885BACE1 2/4885 |
| US-20120302558-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | OTC, GRIK5, GRIN2C | KMT2A 1676/4885LMNA 2246/4885BACE1 69/4885 |
| US-20120172359-A1 | Oxazine Derivatives and their Use in the Treatment of Neurological Disorders | OTC, GRIK5, GRIN2C | KMT2A 1676/4885LMNA 2246/4885BACE1 69/4885 |
| US-20170088547-A1 | N-[2-(3-AMINO-2,5-DIMETHYL-1,1-DIOXIDO-5,6-DIHYDRO-2H-1,2,4-THIADIAZIN-5-YL)-1,3-THIAZOL-4-YL] AMIDES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TBXA2R, TH | KMT2A 2622/4885LMNA 2799/4885BACE1 1739/4885 |
| US-20140088084-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | OTC, GRIK5, GRIN2C | KMT2A 1676/4885LMNA 2246/4885BACE1 69/4885 |
| US-10683287-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | BACE2, BACE1, PSEN2 | KMT2A 2422/4885LMNA 2804/4885BACE1 2/4885 |
| US-10696691-B2 | BACE1 inhibitors | BACE1, BACE2, APP | KMT2A 2749/4885LMNA 1143/4885BACE1 1/4885 |
| US-10246468-B2 | BACE1 inhibitors | BACE1, BACE2, APP | KMT2A 2748/4885LMNA 1187/4885BACE1 1/4885 |
| US-20200048236-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | BACE2, BACE1, PSEN2 | KMT2A 2375/4885LMNA 3044/4885BACE1 2/4885 |
| US-10301296-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | BACE2, BACE1, PSEN2 | KMT2A 2422/4885LMNA 2804/4885BACE1 2/4885 |
| US-20160102105-A1 | BACE1 INHIBITORS | BACE1, BACE2, APP | KMT2A 2749/4885LMNA 1143/4885BACE1 1/4885 |
| US-20170088558-A1 | N-[2-(2-Amino-6,6-Disubstituted-4,4a,5,6-Tetrahydropyrano[3,4-d][1,3]Thiazin-8a(8H)-YL)-1,3-Thiazol-4-YL]Amides | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, UGT1A8, TBXA2R | KMT2A 3138/4885LMNA 2429/4885BACE1 1372/4885 |
| US-20110021520-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | OTC, GRIK5, GRIN2C | KMT2A 1676/4885LMNA 2246/4885BACE1 69/4885 |
| US-20150203481-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | BACE2, BACE1, PSEN2 | KMT2A 2375/4885LMNA 3044/4885BACE1 2/4885 |
| US-20170369506-A1 | N-(2-(2-AMINO-6-SUBSTITUTED-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]OXAZIN-8a(8H)-YL)-THIAZOL-4-YL) AMIDES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP4B1, NPY4R | KMT2A 2749/4885LMNA 1955/4885BACE1 877/4885 |
| US-20170320864-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | BACE2, BACE1, PSEN2 | KMT2A 2375/4885LMNA 3044/4885BACE1 2/4885 |
| US-20140113894-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | OTC, GRIK5, GRIN2C | KMT2A 1676/4885LMNA 2246/4885BACE1 69/4885 |
| US-10035794-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | BACE2, BACE1, PSEN2 | KMT2A 2422/4885LMNA 2804/4885BACE1 2/4885 |
| US-20170088556-A1 | N-(2-(2-AMINO-6-SUBSTITUTED-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]OXAZIN-8a(8H)-YL)-THIAZOL-4-YL) AMIDES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP4B1, NPY4R | KMT2A 2749/4885LMNA 1955/4885BACE1 877/4885 |
| US-20140107118-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | BACE2, BACE1, PSEN2 | KMT2A 2375/4885LMNA 3044/4885BACE1 2/4885 |
| US-20190270757-A1 | BACE1 INHIBITORS | BACE1, BACE2, APP | KMT2A 2749/4885LMNA 1143/4885BACE1 1/4885 |
| US-20190002476-A1 | BACE1 INHIBITORS | BACE1, BACE2, APP | KMT2A 2749/4885LMNA 1143/4885BACE1 1/4885 |
| US-20150018338-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | OTC, GRIK5, GRIN2C | KMT2A 1676/4885LMNA 2246/4885BACE1 69/4885 |
| US-10112958-B2 | N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-YL)-1,3-thiazol-4-YL] amides | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, UGT1A8, TBXA2R | KMT2A 3138/4885LMNA 2429/4885BACE1 1372/4885 |
| US-20120184539-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | BACE2, BACE1, PSEN2 | KMT2A 2375/4885LMNA 3044/4885BACE1 2/4885 |
| US-10253042-B2 | N-(2-(2-amino-6-substituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]oxazin-8a(8H)-YL)-thiazol-4-YL) amides | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP4B1, NPY4R | KMT2A 2749/4885LMNA 1955/4885BACE1 877/4885 |
| US-20120238560-A1 | Oxazine Derivatives and their Use in the Treatment of Neurological Disorders | OTC, GRIK5, GRIN2C | KMT2A 1676/4885LMNA 2246/4885BACE1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.